Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma.
BACKGROUND
We aimed to develop a new biomarker to predict cyclin D1 (CCND1) status using plasma DNA in oesophageal squamous cell carcinoma (ESCC) patients.


METHODS
We evaluated the ratio of the CCND1 (11q13) dosage to the dopamine receptor D2 (DRD2; 11q22-23) dosage (C/D ratio) as CCND1 copy number. This study was divided into three steps: (1) Determination of a cutoff value for the C/D ratio in test scale; (2) Comparison of the C/D ratio in between plasma samples and cancer tissues in ESCC patients showing high plasma C/D ratio; (3) Validation study of the clinical application of the plasma C/D ratio as a diagnostic and prognostic marker, by comparing with clinicopathologic factors in 96 ESCC patients.


RESULTS
The plasma C/D ratio was significantly higher in the ESCC group than the controls (P=0.0134). A high plasma C/D ratio reflected the tumour C/D ratio, and significantly correlated with a poorer prognosis (P=0.0186). Moreover, the high C/D ratio was found to be an independent prognostic factor on multivariate analysis (P=0.0266; hazard ratio 5.988).


CONCLUSIONS
Prediction of CCND1 amplification using plasma DNA is thought to be a promising prognostic biomarker in ESCC patients.
Takeshita
H
H
Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
Ichikawa
D
D
Komatsu
S
S
Tsujiura
M
M
Kosuga
T
T
Deguchi
K
K
Konishi
H
H
Morimura
R
R
Shiozaki
A
A
Fujiwara
H
H
Okamoto
K
K
Otsuji
E
E
D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D019938:Cyclin D1 / Q000235:genetics*; D004273:DNA, Neoplasm / Q000097:blood* / Q000235:genetics; D004938:Esophageal Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D005784:Gene Amplification; D018628:Gene Dosage; D006801:Humans; D016133:Polymerase Chain Reaction; D011379:Prognosis; D017448:Receptors, Dopamine D2 / Q000235:genetics; D012008:Recurrence; D016019:Survival Analysis; D015996:Survival Rate
C530104:CCND1 protein, human; D004273:DNA, Neoplasm; D017448:Receptors, Dopamine D2; D019938:Cyclin D1
Biochim Biophys Acta. 2007 Jan;1775(1):181-232
17137717
Anticancer Res. 2004 Jul-Aug;24(4):2477-81
15330201
J Clin Oncol. 2005 Aug 1;23(22):5205-10
16051962
J Clin Oncol. 2003 Nov 1;21(21):3902-8
14507943
N Engl J Med. 2003 Dec 4;349(23):2241-52
14657432
Crit Rev Oncol Hematol. 2000 Feb;33(2):71-90
10737369
Anticancer Res. 2007 Jul-Aug;27(4C):2737-41
17695440
Clin Cancer Res. 2006 Jul 1;12(13):3915-21
16818687
Proc Natl Acad Sci U S A. 1990 Dec;87(24):9958-61
2263646
Cancer Res. 2001 Sep 15;61(18):6629-34
11559525
Int J Cancer. 2007 Oct 15;121(8):1643-58
17674367
Int J Cancer. 1997 Dec 19;74(6):576-81
9421351
Br J Cancer. 2006 May 22;94(10):1492-5
16641902
Clin Cancer Res. 1996 Jul;2(7):1155-61
9816282
Clin Cancer Res. 2009 Feb 1;15(3):1032-8
19188176
Carcinogenesis. 2009 Jul;30(7):1139-46
19423649
Br J Cancer. 1995 Jan;71(1):64-8
7819051
BMC Cancer. 2009 Jan 07;9:6
19128465
Clin Cancer Res. 1999 Jun;5(6):1381-6
10389922
J Surg Oncol. 2004 Sep 15;87(4):182-6
15334633
Int J Cancer. 1988 Oct 15;42(4):502-5
2459070
Anticancer Res. 2007 Mar-Apr;27(2):1207-12
17465264
Cancer Biol Ther. 2007 Oct;6(10):1553-8
17912028
Clin Chem Lab Med. 2009;47(5):530-6
19302034
Clin Chem. 2002 Aug;48(8):1186-93
12142371
Cancer Res. 1992 May 15;52(10):2980-3
1533816
Nat Med. 2008 Sep;14(9):985-90
18670422
Cancer Res. 1998 May 15;58(10):2057-62
9605741
Anticancer Res. 2007 Jul-Aug;27(4C):2747-51
17695442